Clinical trial
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
NCT06362369 is registered in ClinicalTrials.gov with 7 Hills Pharma, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
- Lead sponsor
- 7 Hills Pharma, LLC
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 23, 2024
- Completion date
- December 31, 2028
- Enrollment
- 126 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cancer, advanced solid tumor, alk genomic tumor aberrations, anaplastic lymphoma kinase genomic tumor aberrations, colorectal cancer, hepatocellular cancer, hepatocellular carcinoma, kidney cancer, melanoma, metastasis, mismatch repair deficiency, msi-high, non small cell lung cancer, nsclc, pleural mesothelioma, renal cell cancer, renal cell carcinoma, skin cancer